Reuters: J&J knew for decades that asbestos lurked in its baby powder

An investigation found that Johnson & Johnson's Baby Powder was sometimes tainted with asbestos, a fact the New Jersey company kept from the public for decades.

A cannabis futurist foresees dirt-cheap weed, THC appetizers, and a big impact from Canada

This Carnegie Mellon University professor predicts the cost of marijuana will fall to near zero and that joints could be given away like chocolates on a hotel pillow. He worries that usage could then explode especially among the poor.

A cannabis futurist foresees dirt-cheap weed, THC appetizers, and a big impact from Canada

This Carnegie Mellon University professor predicts the cost of marijuana will fall to near zero and that joints could be given away like chocolates on a hotel pillow. He worries that usage could then explode especially among the poor.

Pa. auditor general wants to take a whack at firms that negotiate drug benefits for the Medicaid program

Pennsylvania Auditor General Eugene DePasquale wants the state to better manage an entire layer of the Medicaid program -- the pharmacy benefit managers -- who have made millions from the program.

Pa. auditor general wants to take a whack at firms that negotiate drug benefits for the Medicaid program

Pennsylvania Auditor General Eugene DePasquale wants the state to better manage an entire layer of the Medicaid program -- the pharmacy benefit managers -- who have made millions from the program.

J&J, BioMotiv invest $13M in Philly’s Aro Biotherapeutics and its Centyrin protein cancer drugs

The company, based at the University of Pennsylvania’s Pennovation Center, is trying to develop therapies for "undruggable disease."

J&J, BioMotiv invest $13M in Philly’s Aro Biotherapeutics and its Centyrin protein cancer drugs

The company, based at the University of Pennsylvania’s Pennovation Center, is trying to develop therapies for "undruggable disease."
More Stories

Probe of generic ‘cartel’ grows to 300 drugs

What started as an antitrust lawsuit brought by states over just two drugs in 2016 has exploded into an investigation of alleged price-fixing involving at least 16 companies and 300 drugs.

XyloCor raises $17 million to grow heart arteries in Philly gene-therapy deal

XyloCor’s treatment seeks to grow new coronary artery tissue to help patients with severe chest pain (angina) who can’t be treated by surgery.

Percocet maker Endo details how it manages risks from selling opioids

The company disclosed measures it put in place this year to recoup incentive pay from executives.

Merck CEO Ken Frazier rose from humble beginnings in North Philly to run a big pharma company | Industry Icons

After Ken Frazier's 8 years as CEO, the board recently extended his contract. He heads a storied research company but faces challenges especially on drug pricing.

Why Glaxo isn’t meeting with Mayor Kenney while he’s in London

GSK declined the meeting with Mayor Kenney after a City Council bill was submitted that would force drugmakers to register their sales reps. Is there a connection?

Pharmacy benefit managers testify about prescription drugs at Pa. Senate committee hearing

The companies that negotiate drug prices answered pointed questions about costs and where the money is going.

Is Pa. getting shortchanged on drug costs? Legislators want to know.

A state senate hearing on Tuesday will focus on what taxpayers get from pharmacy benefit managers.

Spark Therapeutics pledges 500 new jobs in move to first project in Schuylkill Yards plan

Spark Therapeutics is seeking a larger facility on Market Street in Drexel University's Schuylkill Yards development project.

Blockchain hype may finally turn into reality in pharmaceuticals

A little-noticed U.S. law could bring the ledger system to the pharmaceutical business.

Philly's U.S. attorney going after white collar crime with '100 percent support' from Jeff Sessions

U.S. Attorney William McSwain lays out his plans to pursue white collar crime — with jail time attached.

Canadian marijuana firm Tilray gets rare DEA approval for clinical study

The U.S. Drug Enforcement Agency this morning granted approval to Tilray, Inc. to import research-grade marijuana products from Canada for a clinical trial at the University of California San Diego.

Chinese American scientist admits plot to steal GlaxoSmithKline’s secrets for firm in China

The case is the latest in a string of recent prosecutions of Chinese American scientists accused of purloining trade secrets from U.S. companies in hopes of bolstering China's competitive edge.

The future of medicine may land within five to 10 years, pioneering researcher says

A pioneer of the Crispr gene-editing technology that's taken Wall Street by storm says she's optimistic about their prospects of therapies.

SPECIAL REPORTS
Investigative reports, featured series, and guides to living in the Philadelphia region, brought to you by The Inquirer.
WHAT ARE YOU CURIOUS ABOUT?
Send us your burning questions, or vote on other readers' questions that pique your interest. Our journalists will work to answer them.